New York news anchor goes into labour during broadcast, continues with 3-hour show
Watch
Albany anchor Olivia Jaquith's water broke live on air during her morning broadcast. She continued the three-hour show before heading to the hospital.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
25 minutes ago
- Globe and Mail
$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
$NRXP Has $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). Abbreviated New Drug Application Filed for Preservative-Free IV Ketamine. Current Ketamine Market Estimated at $750 Million and Projected to Reach $3.35 Billion Globally in 2034. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with Universal Capital, LLC. Added to Previously Announced Term Sheet with a Strategic Investor, NRXP HOPE Funding of $10.3 Million is Planned in Near Term. Agreement to Purchase Kadima Neuropsychiatry Institute Expected to Serve as Clinical Model for Treatment Offerings Nationwide. Kadima is a Leading Investigative Site for CNS and Psychedelic Research, Having Served as the Lead Site in Nearly All Major Trials in This Space. Dr. David Feifel, Nationally Recognized Pioneer in Interventional Psychiatry to join as Chief Medical Innovation Officer. New Drug Application for Treatment of Suicidal Depression; Planned NDA for Accelerated Approval for Bipolar Depression in People at Risk of Akathisia. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine. Patent expected to be Orange Book Listable. Waiver Exemption from Paying a $4.3 Million New Drug Application Fee Under Prescription Drug User Fee Act (PDUFA). Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties. Application to Uplist to NASDAQ Global Market from NASDAQ Capital Market NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100. In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link: Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine On June 5th NRXP announced the transmission of its Abbreviated New Drug Application (ANDA) for electronic filing to the U.S. Food and Drug Administration (FDA) for NRX-100, its preservative-free IV ketamine formulation, for use in all existing approved indications such as anesthesia and pain management. NRXP anticipates filing a citizen's petition with the FDA to remove benzethonium chloride, a known neurotoxic and cytotoxic substance, from presentations of ketamine intended for intravenous use. NRXP believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of closely related benzalkonium chloride in current drug products. Preservatives were originally added to sterile injectable products in an era when a single vial of medication was used to treat multiple patients, a practice no longer allowed in US hospitals. NRXP has demonstrated that there is no need for such preservatives to maintain stability and sterility in ketamine presentations intended for single-patient use. Should the citizen's petition be granted, all formulations of ketamine sold in the US could face a regulatory requirement to be preservative free. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions On May 15th NRXP announced signing of a term sheet with Universal Capital, LLC to provide $7.8 million in acquisition capital to initiate subsidiary HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital. HOPE's three initial acquisitions represent best-in-class clinics that offer neuroplastic treatments including NRXP ketamine and transcranial magnetic stimulation (TMS) to treat patients with severe depression, PTSD, and related central nervous system conditions. Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. The FDA has approved TMS devices for a number of indications and has approved a nasal form of ketamine for treatment resistant depression. HOPE's parent company, NRXP, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression. Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the NRXP HOPE Network of Interventional Psychiatry Clinics On May 13th NRXP announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in NRXP HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation (TMS), and hyperbaric therapy. Kadima is one of California's flagship interventional psychiatry clinics and was among the first to bring ketamine treatment for central nervous system (CNS) disorders out of academic research settings and into clinical practice. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, transcranial magnetic stimulation ("TMS") as well as medication management. Further, Kadima and David Feifel, MD PhD, Founder and Medical Director of Kadima, have served as leaders in clinical trial work on emerging therapies in CNS for top companies in the industry. Importantly, the clinic is profitable and is forecast to continue growth going forward. Dr. Feifel will join NRXP HOPE as its first Chief Medical Innovation Officer upon closing of the acquisition. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine On May 5th NRXP announced the filing of a patent application for NRX-100, its preservative-free intravenous ketamine formulation for the treatment of suicidal depression. The application discloses pharmaceutical compositions, methods of treatment and methods of manufacture and currently includes twenty claims. While subject to the patent review process of the US Patent and Trademark Office, if granted, the patent would provide NRX-100 exclusivity into 2045. This patent filing builds on the NRXP recently initiated filing of an NDA for NRX-100 and its prior Fast Track Designation, with NRX-101, from the FDA. If granted, the patent will help protect the innovation behind this formulation as NRXP advances its commercialization strategy. "We are committed to delivering safer, more effective treatments for patients with suicidal depression," said Jonathan Javitt MD MPH, CEO of NRXP. "NRX-100 eliminates the need for benzethonium chloride, a compound with well-documented safety concerns, and reflects our belief that patients in crisis deserve therapies formulated with their long-term well-being in mind. With the recent FDA fee waiver now in place, we remain on track to complete our NDA submission this quarter — a critical step toward bringing this innovation to patients in need." FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression On April 30th NRXP announced the grant of a filing fee waiver by the US Food and Drug Administration ("FDA") to exempt the Company from a $4.3 million fee to file its New Drug Application for NRX-100 (preservative-free ketamine). The waiver is granted at the discretion of the FDA to Small Business Entities and for drugs that are deemed to be necessary for Public Health. NRXP anticipates that this waiver enables the completion of its New Drug Application for NRX-100 with currently-available corporate resources. The NDA filing is anticipated by the end of the second quarter of this year (Q2 2025). Disclosure listed on the CorporateAds website Media Contact Company Name: NRx Pharmaceuticals, Inc. Contact Person: Matthew Duffy, Chief Business Officer Email: Send Email Phone: 484 254 6134 Address: 1201 Orange Street Suite 600 City: Miami State: Florida Country: United States Website:
Globe and Mail
2 hours ago
- Globe and Mail
Financial lessons from a woman whose husband died suddenly at 39
If you can't find the time or motivation to plan financially for your death or a serious illness, please read Jane Blaufus's book. It's called With the Stroke of a Pen: Claim Your Life, and it includes a 33-page checklist of questions for working through the process of helping family members sort through your affairs when you die. The checklist is helpful, but so is Ms. Blaufus's personal experience after the loss of her husband. To hear more, check out this e-mail Q&A I did with Ms. Blaufus: Q: Jane, can you tell us in both a personal and professional sense how you came to write your book? A: My 39-year-old husband walked out the door one Sunday morning, and that afternoon a police officer arrived in my driveway to share the news that he had been killed in an accident. In less than 60 seconds, the world I knew had been turned upside down and I had become a widow with a 12-year-old daughter and a financial tsunami coming my way. By that time, I had been in the life insurance industry for 16 years and had foolishly thought that if anything ever happened to me that I would be better prepared than others. Wrong. I was blindsided by so many unexpected things and thought that if I wasn't prepared, despite all of my knowledge and expertise, what would the average person do in that situation? Fast forward to today and I am happily remarried to a wonderful man who was also widowed after his wife suffered an illness. We collectively decided to pay it forward by sharing our story to help prevent other families from going through what we did. Q: In the conversations you've had with readers, friends, family and clients in your professional life, what have you learned about the capacity people have for preparing for their own death and the death of loved ones? Do we ever get to a point where nine in 10 people have a will, powers of attorney and made other preparations? A: Unfortunately, most people are terrified to talk about death and illness. For many it is like looking their own mortality in the face, but these conversations are crucial because we have an obligation to ourselves and those we love to leave this world in an organized manner. The last thing someone needs when a loved one has become ill or died is to be running around trying to find all the pertinent documents needed to make decisions about medical care or funeral arrangements. Sadly, I do not think we will ever get to the point where nine in ten people will have had these important conversations. Q: If you were to list some of the top things to do to make sure your loved ones are prepared in case of your death, what would they be? A: To start, make sure your loved ones know what your final wishes are. I had asked my husband four times what he would want if anything happened to him and he would always change the subject. When he died, I had to plan a funeral as if I had been blindfolded; it was horrible. Next, make sure you have a current, up-to-date will and powers of attorney for both medical and financial matters. You would not believe the number of times I have heard stories about couples divorcing and the ex-spouse gets everything because the will was never changed. Also, make sure you have enough life insurance for today. Do not stick your policy in a drawer, as things have a way of changing over time. Also, if you have a special needs member of the family, make sure you have provided for them to be cared for in the future. Please make sure all of the beneficiary designations are correct and current as well. And, make sure you have assembled all of your important documentation into one central location, and make sure everyone who should know where it is, does. Your loved ones and your executor should be able to quickly and easily access this information. Speaking of executors, make sure you have asked your executor and legal guardians for your underage children if they willingly accept the role and associated responsibilities. Do not simply assume they will, because if they decline to accept the role after you are gone, you cannot make changes from the grave. Q: What do you think about bringing your adult children into the discussion of what happens when you die? How old should kids be for this conversation? A: This is a very important question, and I believe it is critical to bring them into the discussion, especially today, where there are so many blended families. Having them involved in the conversation can mitigate so many issues that have the potential to erupt after someone dies. As for your question about how old they should be, I would leave this in the parents' hands to determine the age, as they will know their child's maturity level better than anyone else. However, at the latest, I personally would bring them in when they reach adulthood. My poor daughter has had more of these conversations than I think she would care for! Q: Looking back on your own experience when your husband died, what types of advance planning had you done and how did they help in the aftermath? A: The year before my husband died, we had met with our financial advisor to review our investments and life insurance policies. We actually purchased more insurance as things had changed from our last review. The life insurance my husband lovingly put in place for us became a financial lifeline that helped me as I tried to get back on my feet and return to work. We also reviewed our wills with our lawyer, which made settling his estate much easier for me. Q: I've seen some apps and software over the years that were designed to help people organize themselves for when they die, but none seems to have taken off. Do you think the right app could help people engage more with this type of planning, and do you know any apps people should check out? A: I personally do not think an app would engage more people and I do not have a go-to suggestion to offer. What I have done in my book is provide my readers with a checklist designed to help get the conversations going with the people you need to be having them with. It serves as a workbook to help people get their personal and financial lives in order while they can. Are you reading this newsletter on the web or did someone forward the e-mail version to you? If so, you can sign up for Carrick on Money here. Dollarama vs. Costco A nine-product price comparison, including staples like tomato sauce and paper towels. Would you buy a Canadian car? How feasible would it be to tap into Buy Canada sentiment by launching an actual Canadian car company? Foreign companies assemble vehicles in this country, but there are no Canadian automakers. Fixing the problem of too much stuff Advice on de-cluttering from YouTube's The Minimal Mom. The emphasis is on making your living space more comfortable, not throwing a lot of stuff out. Life with the Cybertruck An amusing take on what it's like to drive the Tesla Cybertruck, which starts around $120,000 in Canada. A recent report from J.D. Power shows that in the segment of people who say they are likely to consider an electric vehicle for their next purchase, Tesla has dropped to eighth place after four years among the top two. Subscribe to Stress Test on Apple Podcasts or Spotify. Ask Rob Q: What should the investing approach for seniors be for stocks versus guaranteed income certificates? One, both, neither? A: Both can work well. Stocks for long-term growth and dividend income, GICs to supplement bonds as a source of interest income and stability when stocks decline. An all-stocks approach is too risky for most seniors, while all GICs means a sacrifice of growth for safety. The 5 per cent GIC yields of a few years ago far exceed today's peak rates of 3.5 to 3.95 per cent. Tools and guides This new retirement planning calculator was created by a team including Ben Felix, a portfolio manager who has done a lot of great educational work. In the social sphere Social Media: A LinkedIn discussion about a column I wrote recently about a proposal to tax real estate investment properties. Watch: Toronto's spring housing market: Dead on arrival Money-Free Zone: The band Wye Oak strips down the Kate Bush song Running Up That Hill to the basics, and makes it work. Here's the great, more ornate original version. More PF from The Globe - They downsized to save money and simplify their lives. Here's what they wished they'd known - For travel-loving Canadians, other financial goals take a back seat to vacation spending - When did tipping diverge from a reward for good service to a wage-subsidization tactic?
CTV News
3 hours ago
- CTV News
Luigi Mangione's diary reveals the motive for killing CEO, prosecutors say
Luigi Mangione appears at a hearing for the murder of UHC CEO Brian Thompson at Manhattan Criminal Court on February 21 in New York City. (Curtis Means/Pool/Getty Images via CNN Newsource) Diary entries written by Luigi Mangione reveal the now 27-year-old's detailed thinking before the killing of UnitedHealthcare CEO Brian Thompson last year, a new court filing shows. A red notebook was recovered by police at the time of his December 9 arrest at a McDonald's in Altoona, Pennsylvania. In diary writings contained in that notebook, Mangione vents about his frustrations with the health insurance industry and his intent to carry out an attack. The entries also shed light on Mangione's focus on the court of public opinion and how he intended to gain widespread support through the alleged killing. The new filing from the Manhattan District Attorney's Office is a response to a motion filed last month by Mangione's defence team seeking to stay or dismiss the New York case against him. Mangione has pleaded not guilty to all federal and state charges against him. In August 2024, roughly four months before he allegedly shot and killed Thompson in midtown Manhattan, Mangione wrote in his diary: 'I finally feel confident about what I will do. The details are coming together. And I don't feel any doubt about whether it's right/justified. I'm glad-in a way-that I've procrastinated bc it allowed me to learn more about [UnitedHealthcare].' 'The target is insurance. It checks every box,' he continued in the August 15 entry. That summer, Mangione – who had an active social media presence for years – appeared to stop posting online, prompting worried messages from some of his friends. In October, another diary entry reads, '1.5 months. The investor conference is a true windfall. It embodies everything wrong with our health system, and-most importantly-the message becomes self-evident. The problem with most revolutionary acts is that the message is lost on normies.' He then goes on to explain his reasoning for not targeting the health care industry through a bombing, writing that 'innocent' lives would be unaffected by his attack. At the time of that writing, Mangione – the privileged scion of a well-to-do family, high school valedictorian and Ivy League graduate – had reportedly vanished from view of his loved ones. 'Nobody has heard from you in months, and apparently your family is looking for you,' one user posted on X in October, tagging an account belonging to Mangione. 'I don't know if you are okay,' another posted. Mangione allegedly gunned down Thompson on a busy sidewalk as Thompson walked toward a Manhattan hotel hosting his company's investors' conference, authorities said. The suspect appeared to be driven by anger against the health insurance industry and against 'corporate greed' as a whole, according to an NYPD intelligence report obtained by CNN. The previously unreported writings lay bare Mangione's plans to target the insurance industry. Prosecutors argue in the filing that his actions motivated a barrage of threats against health insurance workers and made them worry for their safety. CNN has reached out to Mangione's attorneys for comment. In the months since the fatal shooting of Thompson, Mangione has become a cult-like figure. There has been a massive outpouring of support on social media and at his court appearances from people with deep frustration and anger at the American for-profit health care system. They see the American health insurance industry as broken, overly expensive and quick to deny coverage. The majority of insured U.S. adults had at least one issue with their health insurance within the span of a year, including denial of claims, according to a survey released in June 2023 by nonprofit health policy research group KFF. A legal defence fund in support of Mangione has raised more than US$1 million as of Wednesday. 'Bombs=terrorism,' Mangione writes In the diary entries, Mangione – who allegedly used a ghost gun to carry out the killing of Thompson – criticizes bombers: 'They commit an atrocity whose horror either outweighs the impact of their message, or whose distance from their message prevents normies from connecting the dots.' In the October 22 entry, Mangione went on to ask, 'Do you bomb the HQ? No. Bombs=terrorism. Such actions appear the unjustified anger of someone who simply got sick/had bad luck and took their frustration out on the insurance industry, while recklessly endangering countless employees.' Instead of carrying out a bombing, targeting the CEO at the conference is 'targeted, precise and doesn't risk innocents,' adding that it would bring light to the event and the 'greed' of its attendees. He also appears to reference the Unabomber, Ted Kaczynski, calling such attacks 'counter-productive' because they would lose public support. 'Normies categorize him as an insane serial killer, focus on the act/atrocities themselves, and dismiss his ideas,' Mangione writes. 'And most importantly—- by committing indiscriminate atrocities he becomes a monster, which makes his ideas those of a monster, no matter how true. He crosses the line from revolutionary anarchist to terrorist-the worst thing a person can be.' The killing sent waves of fear through UHC Mangione's intentions to target the insurance industry were made clear by the writings, which prosecutors say prove that he committed first-degree murder in furtherance of terrorism, the Wednesday filing states. UnitedHealthcare became a symbol of the health insurance industry that Mangione aimed to abolish, prosecutors said. He was not insured by UnitedHealthcare from 2014 to 2024, prosecutors say, but at the time of his arrest, Mangione allegedly had a handwritten notebook that expressed 'hostility toward the health insurance industry and wealthy executives in particular,' according to a federal complaint. 'Having no business relationship with them, he chose UHC solely because they were the largest health insurance company and one of the country's largest companies by market cap,' the new filing said. Notably, three 9mm shell casings from the crime scene had the words 'delay,' 'deny' and 'depose' written on them, the NYPD has said, an apparent nod to a 2010 book critiquing insurance industry tactics. Mangione hoped the alleged killing would intimidate health insurance employees, cause the public to focus on greed in the health insurance industry and prevent investors and financial analysts from investing in the industry, according to the filing. The killing of the husband and father of two struck fear in C-suites across the country, as an NYPD intelligence report obtained by CNN warned online rhetoric could 'signal an elevated threat facing executives in the near-term.' Mangione inspired some individuals to partake in a 'broader campaign of threats of violence' against UnitedHealthcare employees and other health insurance workers, the document says. In the aftermath of Thompson's killing, threats had been aimed at other UnitedHealthcare executives and employees also reported feeling unsafe, prosecutors said. UnitedHealthcare doctors sending out denial letters to customers feared for their safety, requesting that they not be required to sign their names to the letters, prosecutors said. Some physicians quit their jobs out of fear of retribution. The company advised employees not to wear company branded clothes, and online threats prompted it to pull pictures of senior executives from its website, the filing states. Meanwhile, the company's call center received a slew of death threats, the filing said. 'You are gonna hang,' one caller said. 'That means that the killing of Brian Thompson was just a start. There are a lot more that are gonna be taken out. The only question is whether you're gonna be their collateral damage when its done or not.' Police were hired to protect the company's headquarters in Minnesota. Threats were also made to employees at the company's New York City office. Forty company executives received personal security, with one executive who received threats dying her hair and moving into another home out of fear for her safety, according to the filing. Other health insurance executives, including Emblem Health's CEO, were also targeted. Posters were put up outside the company's headquarters with the CEO's picture that read 'Health Care CEOs should not feel safe. Deny, Defend Depose.' The killing 'demonstrated his concerted effort to broadcast his message of ideological intimidation as broadly and loudly as possible,' prosecutors said. By Dalia Faheid, CNN
